
==== Front
Ren Fail
Ren Fail
Renal Failure
0886-022X
1525-6049
Taylor & Francis

39248404
10.1080/0886022X.2024.2399314
2399314
Version of Record
Research Article
Anemia and Hematologic Disorders
Inflammatory indexes and anemia in chronic kidney disease: correlation and survival analysis of the National Health and Nutrition Examination Survey 2005–2018
S. Fu et al.
https://orcid.org/0009-0009-7933-6458
Fu Shaojie a
https://orcid.org/0000-0001-5292-8933
Huang Jingda a
Feng Zhenbang b
Wang Haitao c
Xu Hongzhao a
Wu Meiyan a
Ma Fuzhe a
https://orcid.org/0000-0001-8120-3165
Xu Zhonggao a
a Department of Nephrology, The First Hospital of Jilin University, Changchun, China
b Center of Oncology, The First Hospital of Jilin University, Changchun, China
c Department of Critical Care Medicine, The First Hospital of Jilin University, Changchun, China
Supplemental data for this article can be accessed online at https://doi.org/10.1080/0886022X.2024.2399314.

CONTACT Zhonggao Xu zhonggao@jlu.edu.cn Department of Nephrology, The First Hospital of Jilin University, Changchun, China
9 9 2024
2024
9 9 2024
46 2 239931422 4 2024
17 8 2024
23 8 2024
KnowledgeWorks Global Ltd.7 9 2024
published online in a building issue7 9 2024
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
2024
The Author(s)
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

Abstract

Background

There is currently no research on the correlation between novel inflammatory indexes systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and the risk of anemia in chronic kidney disease (CKD) population, as well as survival analysis in CKD with anemia.

Methods

This investigation encompassed 4444 adult subjects out of the National Health and Nutrition Examination Survey (NHANES) between 2005 and 2018. The study utilized multi-variable logistic regression to assess the relationship between SII, NLR, PLR, and anemia risk occurrence in CKD population. Survival differences in CKD patients with anemia, based on varying levels of SII, NLR, and PLR were evaluated employing Kaplan–Meier and Cox proportional hazards models.

Results

The adjusted logistic regression model demonstrates that SII, NLR, and PLR are associated with the risk of anemia occurrence in CKD population. Kaplan–Meier’s analysis reveals significant differences in survival rates among CKD patients with anemia stratified by NLR levels. The adjusted Cox proportional hazards model shows that the higher NLR group has a 30% elevated risk of all-cause mortality contrasted with lower group (hazard ratio, HR: 1.30, confidence interval (CI) [1.01, 1.66], p value <.04). Restricted cubic spline (RCS) demonstrates no nonlinear relationship between NLR and all-cause mortality. Lastly, sub-cohort analysis indicates that in populations with diabetes, hypertension, and hyperuricemia, NLR levels have a greater impact on all-cause mortality.

Conclusions

Controlling inflammation may reduce the occurrence of anemia in CKD populations, with NLR serving to be a potential prognostic indicator for survival results within CKD patients suffering from co-morbid anemia.

Keywords

Systemic immune-inflammation index
neutrophil-to-lymphocyte ratio
platelet-to-lymphocyte ratio
chronic kidney disease
anemia
NHANES
National Natural Science Foundation of China 10.13039/501100001809 82300831 Natural Science Foundation of Jilin Province 10.13039/100007847 YDZJ202201ZYTS126 20210101259JC Talent Project of Jilin Science and Technology Development 20240602091RC This study was supported by grants from the National Natural Science Foundation of China (No. 82300831), the Natural Science Foundation of Jilin Province (Nos. YDZJ202201ZYTS126 and 20210101259JC), and the Talent Project of Jilin Science and Technology Development (No. 20240602091RC).
==== Body
pmc1. Introduction

Chronic kidney disease (CKD) is characterized as either structural or functional renal impairment persisting for more than three months [1]. A meta-analysis encompassing nearly seven million people showed that the global incidence of CKD is about 11–13% [2]. Therefore, CKD has become a heavy global public health burden. As renal function declines in CKD patients, sodium retention, toxin accumulation, hormonal malfunctions, metabolic disorders, and the state of micro-inflammation will occur, all of which could lead to impairment of blood system [3]. Anemia, a prevalent hematological complication in CKD patients, can manifest early in the disease course, increasing in prevalence and severity as the estimated glomerular filtration rate (eGFR) decreases. Cross-sectional data assessment out of the 2007–2010 National Health and Nutrition Examination Survey (NHANES) indicated that anemia prevalence was doubly high in CKD patients (15.4%) compared to the general population (7.6%). The prevalence of anemia escalated with advancing CKD stages, ranging from 8.4% at phase 1 to 53.4% at phase 5 [4]. Prior research has identified anemia as a risk factor for increased cardiovascular morbidity, hospitalization rates, and diminished quality of life among CKD patients [5]. In addition, anemia significantly increases patients’ economic burden [6]. However, several studies have shown that anemia in patients with CKD is still under identified and under treated to some extent [7,8].

Many metabolites, including endotoxin, hyperphosphate, and homocysteine, are proinflammatory [9–11]. As renal function declines, metabolites gradually accumulate in the body, thus CKD patients are in a chronic inflammatory state [12]. Numerous studies have implicated inflammation in the etiology of renal anemia. Many pro-inflammatory factors are known to inhibit the proliferation of erythroid progenitor cells, affect iron transport, inhibit erythropoietin (EPO) synthesis and activity, and influence erythrocyte longevity [13–15]. Thus, inflammation may be an important risk factor for the development of anemia in the CKD patients. However, due to the cumbersome and expensive detection of traditional inflammation indicators including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP), their application in primary hospitals is limited. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were initially developed by researchers to predict the prognosis of patients with tumors and severe illnesses [16–18], as they are based on counts of peripheral lymphocytes, neutrophils, and platelets, which can better reflect the balance of individual inflammatory and immune status. With continued research into these markers, it has been discovered that these inflammatory indices are associated with the risk of developing chronic inflammatory diseases not related to tumors [19,20] and perform well in predicting the prognosis of non-tumor disease populations [21,22]. Although it is generally accepted that anemia in the CKD population is closely related to the body’s inflammatory state, the relationship between these inflammatory markers and the risk of anemia in the CKD population has not yet been revealed, nor is it clear how they perform in predicting the survival prognosis of the CKD population with anemia.

Hence, this research aims to investigate the association between these novel inflammatory indicators and the risk of developing anemia in CKD population, as well as their relationship with all-cause mortality within the renal anemia population, using the data from NHANES and National Death Index (NDI) databases, to contribute to the improvement of anemia and the reduction of all-cause mortality in CKD patient.

2. Methods

2.1. Study population and data source

This investigation encompassed 4444 adults (20 or older) out of the NHANES performed spanning from 2005 to 2018. NHANES aims to assess the health as well as nutritional condition of grown-ups and children throughout the United States by collecting data via surveys, physical examinations, as well as laboratory tests in various regions. Exclusion criteria for research participants included missing values for hemoglobin (Hb), blood cell count tests, missing data on kidney function-related indicators such as blood creatinine, urine albumin, urine creatinine, missing survival data, as well as missing demographic information and past medical history. The National Center for Health Statistics Ethics Committee approved NHANES project and the informed consent of all NHANES participants can be viewed on the CDC website. Since the data used in this study are publicly available, it is exempt from ethical review involving human subjects. The criteria for participant inclusion and exclusion are detailed in Figure 1.

Figure 1. Screening process flowchart for participant selection. PIR: ratio of family income to poverty; CKD: chronic kidney disease; CVD: cardiovascular disease; BMI: body mass index.

2.2. Inflammatory index

Data on leukocyte counts (neutrophils, lymphocytes, and platelets) obtained from NHANES were utilized to compute the SII, NLR, as well as PLR [23]. Samples with values that deviate significantly from the overall distribution will be excluded to avoid skewing the results. The formulas used are: SII = platelet count multiplied by neutrophil count divided by lymphocyte count; NLR = neutrophil count divided by lymphocyte count; PLR is platelet count divided by lymphocyte count. Based on these quartiles of these inflammatory markers, participants were categorized to high and low groups, with those above the 3/4 quartile classified as the high group and those below the 3/4 quartile classified as the low group.

2.3. Anemia

Anemia was identified employing the World Health Organization’s diagnostic criteria: adult males having serum Hb degrees below 13 g/dL as well as non-pregnant adult females with levels below 12 g/dL were categorized as ­anemic [24].

2.4. Chronic kidney disease

The diagnosis of CKD follows the clinical practice recommendations for CKD outlined in Kidney Disease: Enhancing Global Outcomes (KDIGO) 2020 [25]: (1) kidney damage (structural or functional) persisting for more than 3 months, including histological or imaging abnormalities, tubular damage, abnormal urine sediment, proteinuria, or a kidney transplantation history, with or without a decreased glomerular filtration rate (GFR); (2) decrease in GFR of unknown cause persisting for more than 3 months. The phase of CKD is decided by the KDIGO consensus [26] and is based on the eGFR derived employing the CKD Epidemiology Collaboration algorithm. These steps are explained in the following manner: classification of renal function stages: stage I: optimal renal performance characterized by a GFR of 90 mL/(min·1.73 m2) or higher. Stage II: A slight reduction in renal efficiency, with GFR values ranging between 60 and 89 mL/(min·1.73 m2). Stage IIIa: Mild to moderate decline in renal function, as indicated by a GFR between 45 and 59 mL/(min·1.73 m2). Stage IIIb: Moderate reduction in kidney function, with GFR levels spanning between 30 and 44 mL/(min·1.73 m2). Stage IV: Significant impairment in renal function, indicated by a GFR between 15 and 29 mL/(min·1.73 m2). Stage V: Renal failure, identified by a GFR of less than 15 mL/(min·1.73 m2).

2.5. Primary outcome

The principal outcome assessed was all-cause mortality. Survival data for participants were acquired through linkage with the NDI public dataset (https://www.cdc.gov/nchs/data-linkage/mortality-public.htm). Recorded details for deceased subjects included their death date and death cause, categorized employing the International Classification of Diseases, 10th Edition (ICD-10) codes.

2.6. Covariates

Information regarding demographic characteristics, lifestyle factors, and health status was collected from NHANES 2005–2018. Demographic characteristics included age, sex, race (non-Hispanic white, Mexican American, non-Hispanic black, other Hispanic, other race), education status (less than 9th grade, 9–11th grade, high school graduate or equivalent, some college or AA degree, college graduate or above), ratio of family income to poverty (PIR) [27]. Lifestyle information included smoking status (never smoked, former smoker, current smoker) and alcohol consumption status (non-drinker, drinker) [28]. Health information included body mass index (BMI), history of diabetes (Hb A1C concentration ≥6.5%, fasting blood glucose ≥126 mg/dL, or self-reported diabetes) [29], history of hypertension (average of three consecutive measurements of systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg, self-reported history of hypertension, or use of antihypertensive medication), history of hyperuricemia (serum uric acid level ≥420 μmol/L for men, ≥360 μmol/L for women) [30], and history of cardiovascular disease (coronary heart disease, congestive heart failure, angina pectoris, stroke, myocardial infarction).

2.7. Data analysis

The analysis used sample weights to make the results representative of the US community population. Characteristics of the NHANES 2005–2018 sample were segmented into two groups based on anemia diagnosis. The comparison of continuous and categorical variables between these groups utilized the Wilcoxon rank-sum and the Chi-square testing, respectively. Multi-variable logistic regression was applied to compute odds ratios (ORs) with 95% confidence intervals (CIs) for examining the associations involving the SII, NLR, PLR, and anemia risk in the CKD population. Additionally, we analyzed the relationship between inflammation markers and red blood cell counts. Metabolic byproducts in the CKD population, such as indoxyl sulfate and inorganic phosphates, are involved in processes related to red blood cell death (see Supplementary Table 1). Kaplan–Meier’s estimates evaluated disparities in all-cause mortality among CKD patients with varying levels of SII, NLR, and PLR. Additionally, models for Cox proportional hazards quantified hazard ratios (HRs) with 95% CIs to assess the effects of inflammation levels on mortality in anemic CKD patients. To thoroughly account for confounders, three analytical models were developed: model 1 performed univariate analyses solely on inflammation levels; model 2 incorporated demographic factors such as age, gender, race, education, and PIR; in model 3, additional adjustments were made for various demographic factors, including gender, race, age, education, PIR, BMI, smoking history, alcoholic beverage history, diabetes, hypertension, hyperuricemia, cardiovascular disease history, as well as the CKD phase. Furthermore, the study employed multi-variable Cox proportional hazards models using limited cubic spline curves to investigate potential nonlinear associations between inflammatory markers and death at the fifth, 35th, 65th, and 95th percentages of these markers. Stratified analyses determined the consistency of the relationship between NLR and mortality across various subgroup, segmented by gender, age, alcohol consumption, hypertension, diabetes, hyperuricemia, and CKD stage. R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria) was employed for conducting statistical analysis. All experiments performed were two-sided, and a significance level of .05 was employed to establish statistical significance.

3. Findings

3.1. Baseline characteristics of the participants

A total of 4444 American adults diagnosed with CKD were included, among whom 847 participants had anemia (Table 1; attributes of the anemia group are provided within Supplementary Table 2). The average age of participants was 60.64 (±0.39) years, with females accounting for 52.27%. In the anemia group, the average Hb concentration was 11.35 (±0.04) g/dL, as well as the average eGFR was 57.52 (±1.35) mL/(min·1.73 m2). The mean values of SII, NLR, and PLR were 703.57 (±29.39), 2.77 (0.08), and 152.63 (3.55), respectively. Additionally, participants with anemia had a lower proportion of smokers, drinkers, and obesity, and a higher proportion of hypertension, diabetes, and hyperuricemia.

Table 1. Characteristics of CKD participants aged 20 years and older from the NHANES 2005 to 2018.

Characteristics	Total (N = 4444)	Non-anemia (N = 3597)	Anemia (N = 847)	p Value	
Age (years)	60.64 (0.39)	59.65 (0.42)	66.53 (0.68)	<.0001	
Gender	 	 	 	.92	
 Female	2323 (52.27)	1890 (57.26)	433 (57.05)	 	
 Male	2121 (47.73)	1707 (42.74)	414 (42.95)	 	
Race	 	 	 	<.0001	
 Non-Hispanic White	2230 (50.18)	1897 (73.81)	333 (59.68)	 	
 Mexican American	593 (13.34)	497 (6.80)	96 (6.60)	 	
 Non-Hispanic Black	977 (21.98)	671 (9.68)	306 (24.46)	 	
 Other Hispanic	350 (7.88)	287 (4.27)	63 (4.46)	 	
 Other race	294 (6.62)	245 (5.44)	49 (4.80)	 	
Education status	 	 	 	<.0001	
 Less than 9th grade	664 (14.94)	499 (8.06)	165 (13.96)	 	
 9–11th grade	741 (16.67)	598 (13.18)	143 (15.66)	 	
 High school grade	1092 (24.57)	880 (24.93)	212 (27.36)	 	
 College	1190 (26.78)	977 (30.65)	213 (25.79)	 	
 College graduate or above	757 (17.03)	643 (23.18)	114 (17.23)	 	
PIR	2.70 (0.05)	2.75 (0.05)	2.35 (0.07)	<.0001	
BMI (kg/m2)	 	 	 	.39	
 <18.5	80 (1.8)	70 (2.17)	10 (1.57)	 	
 18.5–24	782 (17.6)	606 (18.49)	176 (21.15)	 	
 24–27	777 (17.48)	625 (17.10)	152 (18.48)	 	
 >27	2805 (63.12)	2296 (62.25)	509 (58.80)	 	
Smoking	 	 	 	<.0001	
 Never smoker	2200 (49.5)	1746 (49.62)	454 (53.57)	 	
 Former smoker	1467 (33.01)	1169 (32.39)	298 (36.28)	 	
 Current smoker	777 (17.48)	682 (17.99)	95 (10.15)	 	
Drinking	 	 	 	<.0001	
 No	1538 (34.61)	1186 (29.37)	352 (39.35)	 	
 Yes	2906 (65.39)	2411 (70.63)	495 (60.65)	 	
Diabetes	 	 	 	<.0001	
 No	2711 (61)	2267 (68.77)	444 (57.65)	 	
 Yes	1733 (39)	1330 (31.23)	403 (42.35)	 	
Hypertension	 	 	 	<.0001	
 No	1015 (22.84)	877 (28.38)	138 (15.93)	 	
 Yes	3429 (77.16)	2720 (71.62)	709 (84.07)	 	
CKD stage	 	 	 	<.0001	
 G1–G2	2286 (51.44)	1998 (55.61)	288 (33.01)	 	
 G3–G5	2158 (48.56)	1599 (44.39)	559 (66.99)	 	
Hyperuricemia	 	 	 	<.0001	
 No	2919 (65.68)	2440 (68.16)	479 (57.11)	 	
 Yes	1525 (34.32)	1157 (31.84)	368 (42.89)	 	
CVD	 	 	 	<.0001	
 No	3220 (72.46)	2686 (78.24)	534 (62.85)	 	
 Yes	1224 (27.54)	911 (21.76)	313 (37.15)	 	
 Hb (g/dL)	13.86 (0.04)	14.28 (0.03)	11.35 (0.04)	<.0001	
 eGFR (mL/(min·1.73 m2))	72.56 (0.59)	75.10 (0.66)	57.42 (1.33)	<.0001	
 Scr (mg/dL)	1.12 (0.01)	1.05 (0.01)	1.54 (0.05)	<.0001	
 Uric acid (μmol/L)	354.89 (1.98)	350.92 (1.99)	378.57 (5.50)	<.0001	
 SII	613.59 (8.92)	598.64 (8.49)	702.77 (29.49)	<.001	
 NLR	2.53 (0.03)	2.49 (0.03)	2.77 (0.08)	.002	
 PLR	133.25 (1.35)	130.06 (1.31)	152.26 (3.57)	<.0001	
 Red blood cell count (million cells/μL)	4.54 (0.01)	4.65 (0.01)	3.88 (0.02)	<.0001	
PIR: ratio of family income to poverty; BMI: body mass index; CKD: chronic kidney disease; CVD: cardiovascular disease; Hb: hemoglobin; eGFR: estimated glomerular filtration rate; Scr: serum creatinine; SII: systemic immune-inflammation index; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio.

Continuous variables with a normal distribution were presented as mean values along with their standard deviations (SDs), while categorical variables were expressed as proportions. The Wilcoxon rank-sum test was employed to compare continuous variables, and Chi-square testing was utilized for categorical variables. We adjusted for sample weights from the mobile examination center to ensure the representativeness of results for the US civilian resident population.

3.2. Relationship between inflammatory indexes and risk of anemia among CKD population

The study utilized multi-variable logistic regression analysis to explore the correlations between SII, NLR, PLR and the risk of anemia in the CKD population. Model 1 initially demonstrated a strong correlation between elevated levels of inflammatory indices and a higher risk of anemia among individuals with CKD. Subsequent adjustments in model 3 for age, gender, race, educational attainment, PIR, BMI, smoking, and alcohol use histories, as well as histories of hypertension, diabetes, hyperuricemia, cardiovascular disease, and CKD stage, confirmed the persistence of these associations. Specifically, the correlation with SII (OR: 1.56, 95% CI [1.16, 2.11], p value <.005) and NLR (OR: 1.44, 95% CI [1.00, 2.07], p value <.05) was intensified, whereas the association with PLR (OR: 1.75, 95% CI [1.33, 2.30], p value <.001) slightly diminished (Table 2).

Table 2. The relationship between SII, NLR, PLR, and the risk of anemia occurrence in CKD patients.

Inflammatory index	Group	Anemia/total	OR (95% CI), p value	
Model 1a	Model 2b	Model 3c	
SII	Low	516/3000	–	
High	331/1444	1.48 (1.20, 1.84)	.001	1.55 (1.16, 2.07)	.004	1.56 (1.16, 2.11)	.005	
NLR	Low	503/2873	–	
High	344/1571	1.40 (1.13, 1.73)	.002	1.55 (1.10, 2.19)	.01	1.44 (1.00, 2.07)	.05	
PLR	Low	496/3086	–	
High	351/1358	1.88 (1.58, 2.25)	.0001	1.82 (1.40, 2.38)	.0001	1.75 (1.33, 2.30)	.001	
OR: odd rate; –: reference; CI: confidence interval; PIR: ratio of family income to poverty; CKD: chronic kidney disease; SII: systemic immune-inflammation index; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio.

Sampling weights were considered in logistic regression analyses to obtain nationally representative estimates.

a Unadjusted.

b Adjusted for gender, age, race, education status, and PIR.

c Model 2 + adjusted for smoking history, drinking history, hypertension, diabetes, hyperuricemia history, cardiovascular disease history, and CKD stage.

3.3. Relationship between inflammatory indices and all-cause mortality in anemic CKD patients

Among the 847 individuals diagnosed with CKD and anemia, 390 deaths succumbed over a median monitoring period of 71 months. Kaplan–Meier’s curves illustrated a significantly elevated mortality rate among anemic CKD patients within the high NLR group compared to their counterparts in the low NLR group (p value <.0001) (Figure 2). However, mortality rates showed no variance when assessed against SII and PLR levels. The unadjusted Cox proportional hazards model revealed a 57% increase in mortality risk for the high NLR cohort relative to the low NLR cohort (HR: 1.57, CI [1.24, 2.00], p value <.001). This finding remained consistent in model 3, which adjusted for demographic and health variables including age, sex, race, educational attainment, PIR, BMI, smoking, and alcohol consumption histories, as well as histories of hypertension, diabetes, hyperuricemia, cardiovascular disease, and CKD phase (HR: 1.30, CI [1.01, 1.66], p value <.04) (Table 3). Nonetheless, no significant correlations were observed between SII, PLR, and survival rates in CKD patients with anemia. Restricted cubic spline (RCS) analysis indicated an absence of a nonlinear relationship between NLR as a continuous variable and all-cause mortality in anemic CKD patients (p-nonlinear = .06) (Figure 3).

Figure 2. The cumulative incidence of all-cause death in the groups of high and low SII, NLR, PLR levels during the follow-up period. SII: systemic immune-inflammation index; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio.

Figure 3. Restricted cubic spline (RCS) analyses between NLR and all-cause mortality of CKD participants with anemia. NLR: neutrophil-to-lymphocyte ratio.

Table 3. The relationship between SII, NLR, PLR, and the all-cause mortality rate of CKD patients with anemia.

Inflammatory index	Group	Death/total	HR (95% CI), p value	
Model 1a	Model 2b	Model 3c	
SII	Low	230/516	–	
High	160/331	1.04 (0.81, 1.34)	.7	0.90 (0.67, 1.23)	.5	0.88 (0.62, 1.25)	.5	
NLR	Low	203/503	–	
High	187/344	1.57 (1.24, 2.00)	<.001	1.28 (1.02, 1.60)	.034	1.30 (1.01, 1.66)	.04	
PLR	Low	226/496	–	
High	164/351	0.84 (0.66, 1.07)	.2	0.85 (0.67, 1.09)	.2	0.81 (0.62, 1.05)	.12	
HR: hazard ratio; –: reference; CI: confidence interval; PIR: ratio of family income to poverty; CKD: chronic kidney disease; SII: systemic immune-inflammation index; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio.

Sampling weights were considered in Cox proportional hazards model analyses to obtain nationally representative estimates.

a Unadjusted.

b Adjusted for gender, age, race, education status, and PIR.

c Model 2 + adjusted for smoking history, drinking history, hypertension, diabetes, hyperuricemia history, cardiovascular disease history, and CKD stage.

3.4. Sub-cohort analysis and sensitivity analysis

Stratified analysis was utilized to evaluate whether the association involving NLR and all-cause mortality among CKD patients suffering from anemia was consistent across different demographic characteristics and comorbidities. The results revealed that in subcohorts with hypertension (HR: 1.346, CI [1.083, 1.673], p value <.007), diabetes (HR: 1.554, CI [1.164, 2.075], p value <.003), and hyperuricemia (HR: 1.556, CI [1.162, 2.084], p value <.003), higher NLR levels were associated with an amplified effect on mortality among CKD patients with anemia (Figure 4). Furthermore, there was evidence of interaction between high NLR levels and hyperuricemia on mortality among CKD patients with anemia (HR: 1.556, CI [1.162, 2.084], p value <.003, p for interaction: .048). In a sensitivity analysis aimed at assessing potential reverse causation, participants who passed away within a 24-month period of follow-up were excluded. Comparable outcomes were obtained in the Cox proportional hazards model (Supplementary Table 3). To assess whether the exclusion of samples due to missing covariates would impact the robustness of our conclusions, we conducted a separate Cox regression analysis on the excluded samples alone. Additionally, we merged these excluded samples with the included samples to perform another Cox regression analysis. The results confirmed that the conclusions remain unchanged despite the exclusion of samples (Supplementary Table 4).

Figure 4. Subgroup analyses of the associations between NLR and all-cause mortality among CKD participants with anemia from the NHANES 2005–2018. NLR: neutrophil-to-lymphocyte ratio; CKD: chronic kidney disease; HR: hazard ratio.

4. Discussion

This investigation delved into the impact of novel inflammatory markers, SII, NLR, as well as PLR, upon the incidence of renal anemia within individuals suffering from CKD, as well as the all-cause mortality within this group, utilizing data from the NHANES spanning 2005 to 2018. Increased SII, NLR, and PLR levels were all found to be correlated with an elevated risk of renal anemia in CKD patients, as well as the elevated level of NLR increased all-cause mortality in renal anemia population, which was aggravated by old age, obesity, hypertension, diabetes, and hyperuricemia.

CKD patients have the serologic evidence of activation of the inflammatory response, such as elevated levels of CRP and pro-inflammatory cytokine [31]. As renal function declines, the accumulation of pro-inflammatory metabolites in the body is the key cause of inflammation [11]. In addition, oxidative stress levels are augmented in CKD and can be mutually enhanced with inflammatory responses. For example, reactive oxygen species production and reactive nitrogen are promoted by toxins accumulated in CKD such as asymmetric dimethylarginine, which results in protein oxidation, DNA cleavage, and impairment of the mitochondrial electron transport cascade [32], whereas the activation of the NF-κB signaling pathway in peroxidized environments could promote the expression of inflammation-stimulating factors and facilitate the recruitment of inflammatory cells [33]. Moreover, the reduced intestinal barrier function in CKD patient also aggravates the level of inflammation in body. Toxins accumulated in the body are excreted from the intestinal system, disturbing the balance of the intestinal flora and leading to the overgrowth of ammonia-producing bacteria, which may increase the risk of invasion for certain bacteria and cause an inflammatory response [34, 35].

The relationship between inflammation and anemia has been confirmed across different populations. Previous studies have confirmed that SII and NLR are associated with the risk of anemia in the general population [36, 37], and in non-CKD chronic immune activation populations (such as those with rheumatoid arthritis and older cancer patients), NLR and PLR are related to the risk of anemia [38, 39]. Additionally, many studies have demonstrated that inflammation is also associated with the development and progression of renal anemia. Francisco et al. showed that high CRP level is a good predictor of poor Hb control in CKD patients [31]. Pro-inflammatory factors have been shown to affect erythropoiesis through a variety of mechanisms. Allen et al. found that pro-inflammatory factors in the serum of patients with end-stage renal disease and inflammatory diseases could inhibit the colony formation of erythropoiesis [40]. In vivo study confirmed that TNF-α can promote hypoproliferative anemia by directly affecting erythroid progenitor cells and indirectly stimulating IFN-γ production [41]. The effect of systemic inflammatory activation on iron transport is also an important factor contributing to anemia in CKD patients. Macrophages recycle iron from aging erythrocytes, which constitute approximately 90% of daily iron necessities for Hb production and erythropoiesis. Nevertheless, these cells also respond to microbial, autoantigen, or tumor antigen exposures, immune cells release a variety of inflammatory cytokines and affect iron metabolism [42]. IL-1 and IL-6 can affect iron homeostasis by influencing heparin formation and stimulating Hb synthesis [43]. Hepcidin regulates iron metabolism via binding to transmembrane iron transport proteins and leading to their degradation [44]. Elevated hepcidin levels correlate with diminished ferritin expression in duodenal epithelial cells and macrophages, alongside compromised iron uptake and storage by macrophages, as observed in animal models of inflammatory anemia and individuals with inflammatory diseases [45]. Decrease in EPO synthesis as well as activity is another causative factor of inflammatory anemia. Observational studies have shown that most patients with inflammatory anemia have lower levels of EPO than expected [13]. This may result from the fact that some of the inflammatory factors (e.g., IL-1, TNF) affect the hypoxia-mediated EPO production process by inhibiting GATA-2 and NF-κB activities or damaging renal tubular epithelial cells [46, 47]. In addition, a shortening of erythrocyte lifespan can be observed in the inflammatory. Causes include increased phagocytosis of erythrocytes by hepatic and splenic macrophages, destruction of erythrocytes by antibodies and complement, and mechanical damage to erythrocytes by fibrin deposition in the microvasculature, during inflammation [14, 15, 48]. Above studies support our findings that the level of inflammation is correlated with the risk of anemia in CKD patients, suggesting that preventing or controlling the inflammatory state within CKD patients may be a way to improve the incidence of anemia in CKD population.

NLR, PLR, and SII were initially developed by researchers to predict the prognosis of patients with tumors and severe illnesses [16–18], as they are based on counts of peripheral lymphocytes, neutrophils, and platelets, which can better reflect the balance of individual inflammatory and immune status. Due to their lower testing costs and convenient detection methods, these markers are used to predict the prognosis of various chronic inflammatory disease populations [21, 22]. Therefore, exploring their potential to predict survival outcomes in CKD patients with anemia is a worthwhile endeavor. Our research also indicates a strong correlation between elevated NLR and heightened all-cause mortality in populations with renal anemia. This increased mortality risk is attributable to inflammation, which serves as a pivotal mediator linking CKD and cardiovascular disease. Crucially, the interactions between endothelial cells and effector cells of the innate immune system are central to the initiation and progression of inflammation. CKD prompts various metabolic alterations that exacerbate the uremic milieu, leading to the accumulation of diverse uremic toxins. These toxins induce vascular damage, endothelial dysfunction, and activation of the innate immune system. The resultant endothelial dysfunction triggers oxidative stress, augments the expression of leukocyte adhesion molecules, and perpetuates chronic inflammation [49]. Recent research has highlighted monocyte-driven changes in CKD, which exacerbate endothelial dysfunction and thereby accelerate the progression of CKD and its associated cardiovascular diseases [50, 51]. Inflammatory state strikes the cardiovascular system of CKD patients may be an important way to influence the prognosis of CKD patients. However, unlike NLR, PLR, and SII, which use platelet count as the numerator, did not demonstrate satisfactory predictive performance in the CKD population with anemia. In cancer patients, platelets can protect circulating tumor cells from shear stress, induce epithelial–mesenchymal transitions in circulating tumor cells, and promote the extravasation of tumor cells [52, 53]. This may explain why PLR and SII perform well in predicting the prognosis of cancer patients but do not show similar effectiveness in the CKD population with anemia.

Clinical application of inflammatory factors is limited by their complex and costly detection techniques, while novel inflammatory indicators are gradually being used in clinical studies to predict the prognosis of chronic inflammatory diseases due to their ease of detection and low cost. A multicenter cohort study conducted across 39 centers in China found that NLR levels are predictive of the risk for end-phase renal disease within individuals suffering from stage 4 CKD [54]. Similarly, a meta-analysis identified NLR as a prognostic marker for all-cause mortality as well as cardiovascular events within patients suffering from CKD [55]. A cohort study involving five centers in China reported that elevated SII levels independently predict higher risks of all-cause, cardiovascular, and cancer mortality in non-dialysis CKD patients [56]. Additionally, another study noted that each unit increase in SII is correlated to a 20.2% rise in all-cause mortality as well as a 28% increase in cardiovascular mortality among peritoneal dialysis patients [57], while our study did not observe a significant relationship between SII and mortality in renal anemia population. This may because our survival analyses were conducted using data from non-Asian populations, suggesting that the relationship between SII and patient mortality may be influenced by ethnicity.

Drawing on prior research, we focused our investigation on CKD patients who also suffered from anemia. Our findings not only established correlations between SII, NLR, as well as PLR levels and the risk of anemia development within CKD patients but also linked higher NLR levels with increased all-cause mortality within this group. These observations suggest that managing inflammation may enhance both anemia outcomes and overall prognosis in the CKD patient population. However, several limitations accompany our study. Primarily, since non-Hispanic whites predominate within the NHANES dataset, these results may not be generalizable to other racial groups, underscoring the need for further validation across diverse populations. Second, the cross-sectional nature of NHANES hinders our ability to ascertain causal relationships between novel inflammatory markers and renal anemia. Lastly, unknown confounding variables and potential biases in survey responses may also impact the study results.

5. Conclusions

This study found that in the CKD population, inflammatory markers such as NLR, PLR, and SII are associated with the risk of developing anemia. Specifically, an increase in NLR is associated with a higher risk of mortality in the CKD population with anemia. This relationship is more pronounced in subgroups with comorbid conditions such as hypertension, diabetes, and hyperuricemia.

Supplementary Material

Supplemental Material

Acknowledgements

We thank to the National Center for Health Statistics at the CDC for their excellent work in collecting the NHANES data and for making it accessible to the public.

Author contributions

S.F. and J.H. conceptualized the research topic and framework; Z.F. and H.W. identified the methodological details of the research; H.X. and M.W. used statistical software for data analysis; S.F. and F.M. wrote the main manuscript text; Z.X. conducted writing-review and editing. All authors reviewed the manuscript.

Ethical approval

The CDC/NCHS Research Ethics Review Board granted approval for the detailed methods and protocols employed in the NHANES study.

Consent form

The procedures, including informed consent protocols for participants, can be accessed on the CDC.gov website. All methods adhered to the applicable guidelines and regulations. Since the data used in this study are publicly available, it was exempt from ethical review involving human subjects.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

All data can be downloaded from the NHANES website (https://www.cdc.gov/nchs/nhanes/about_nhanes.htm).
==== Refs
References

1 Huang J, Yu Y, Li H, et al. Effect of dietary protein intake on cognitive function in the elderly with chronic kidney disease: analysis of the National Health and Nutrition Examination Survey 2011–2014. Ren Fail. 2023;45 (2 ):2294147. doi: 10.1080/0886022X.2023.2294147.38097960
2 Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLOS One. 2016;11 (7 ):e0158765. doi: 10.1371/journal.pone.0158765.27383068
3 Olsen E, van Galen G. Chronic renal failure-causes, clinical findings, treatments and prognosis. Vet Clin North Am Equine Pract. 2022;38 (1 ):25–46. doi: 10.1016/j.cveq.2021.11.003.35365250
4 Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLOS One. 2014;9 (1 ):e84943. doi: 10.1371/journal.pone.0084943.24392162
5 Palaka E, Grandy S, van Haalen H, et al. The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes—a systematic literature review. Int J Nephrol. 2020;2020 :7692376. doi: 10.1155/2020/7692376.32665863
6 Nissenson AR, Wade S, Goodnough T, et al. Economic burden of anemia in an insured population. J Manag Care Pharm. 2005;11 (7 ):565–574. doi: 10.18553/jmcp.2005.11.7.565.16137214
7 Xu Y, Evans M, Mazhar F, et al. Poor recognition and undertreatment of anemia in patients with chronic kidney disease managed in primary care. J Intern Med. 2023;294 (5 ):628–639. doi: 10.1111/joim.13702.37463872
8 Kimura T, Snijder R, Nozaki K. Diagnosis patterns of CKD and anemia in the Japanese population. Kidney Int Rep. 2020;5 (5 ):694–705. doi: 10.1016/j.ekir.2020.03.006.32405590
9 Suzuki K. Chronic inflammation as an immunological abnormality and effectiveness of exercise. Biomolecules. 2019;9 (6 ):223. doi: 10.3390/biom9060223.31181700
10 Martínez-Moreno JM, Herencia C, de Oca AM, et al. High phosphate induces a pro-inflammatory response by vascular smooth muscle cells and modulation by vitamin D derivatives. Clin Sci. 2017;131 (13 ):1449–1463. doi: 10.1042/CS20160807.
11 Hamlett L, Haragsim L. Quotidian hemodialysis and inflammation associated with chronic kidney disease. Adv Chronic Kidney Dis. 2007;14 (3 ):e35–e42. doi: 10.1053/j.ackd.2007.03.006.17603973
12 Huang J, Li H, Yang X, et al. The relationship between dietary inflammatory index (DII) and early renal injury in population with/without hypertension: analysis of the National Health and Nutrition Examination Survey 2001–2002. Ren Fail. 2024;46 (1 ):2294155. doi: 10.1080/0886022X.2023.2294155.38178375
13 Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123 (5 ):615–624. doi: 10.1182/blood-2013-06-508325.24297872
14 Libregts SF, Gutiérrez L, de Bruin AM, et al. Chronic IFN-γ production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis. Blood. 2011;118 (9 ):2578–2588. doi: 10.1182/blood-2010-10-315218.21725055
15 Mitlyng BL, Singh JA, Furne JK, et al. Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases. Am J Hematol. 2006;81 (6 ):432–438. doi: 10.1002/ajh.20644.16680757
16 Hu B, Yang X-R, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20 (23 ):6212–6222. doi: 10.1158/1078-0432.CCR-14-0442.25271081
17 Smith RA, Ghaneh P, Sutton R, et al. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet–lymphocyte ratio. J Gastrointest Surg. 2008;12 (8 ):1422–1428. doi: 10.1007/s11605-008-0554-3.18543046
18 Zahorec R. Ratio of neutrophil to lymphocyte counts – rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102 (1 ):5–14.11723675
19 Liu K, Tang S, Liu C, et al. Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk. Front Immunol. 2024;15 :1337241. doi: 10.3389/fimmu.2024.1337241.38481995
20 Tudurachi BS, Anghel L, Tudurachi A, et al. Assessment of inflammatory hematological ratios (NLR, PLR, MLR, LMR and monocyte/HDL–cholesterol ratio) in acute myocardial infarction and particularities in young patients. Int J Mol Sci. 2023;24 (18 ):14378. doi: 10.3390/ijms241814378.37762680
21 Colaneri M, Genovese C, Fassio F, et al. Prognostic significance of NLR and PLR in COVID-19: a multi-cohort validation study. Infect Dis Ther. 2024;13 (5 ):1147–1157. doi: 10.1007/s40121-024-00967-6.38643431
22 Kocyigit I, Eroglu E, Unal A, et al. Role of neutrophil/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease. J Nephrol. 2013;26 (2 ):358–365. doi: 10.5301/jn.5000152.22573523
23 Tang Y, Peng B, Liu J, et al. Systemic immune-inflammation index and bone mineral density in postmenopausal women: a cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2007–2018. Front Immunol. 2022;13 :975400. doi: 10.3389/fimmu.2022.975400.36159805
24 World Health Organization; 2024. Available from: https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf
25 KDIGO 2020. Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98 (4s ):S1–S115.32998798
26 Lameire NH, Levin A, Kellum JA, et al. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2021;100 (3 ):516–526. doi: 10.1016/j.kint.2021.06.028.34252450
27 Wang S, Xiao W, Duan Z, et al. Depression heightened the association of the systemic immune-inflammation index with all-cause mortality among osteoarthritis patient. J Affect Disord. 2024;355 :239–246. doi: 10.1016/j.jad.2024.03.127.38552917
28 Di X, Liu S, Xiang L, et al. Association between the systemic immune-inflammation index and kidney stone: a cross-sectional study of NHANES 2007–2018. Front Immunol. 2023;14 :1116224. doi: 10.3389/fimmu.2023.1116224.36895572
29 Di XP, Gao XS, Xiang LY, et al. The association of dietary intake of riboflavin and thiamine with kidney stone: a cross-sectional survey of NHANES 2007–2018. BMC Public Health. 2023;23 (1 ):964. doi: 10.1186/s12889-023-15817-2.37237348
30 Huang J, Zhang Y, Li J, et al. Association of dietary inflammatory index with all-cause and cardiovascular disease mortality in hyperuricemia population: a cohort study from NHANES 2001 to 2010. Medicine. 2023;102 (51 ):e36300. doi: 10.1097/MD.0000000000036300.38134106
31 de Francisco AL, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus. 2009;2 (Suppl. 1 ):i18–i26. doi: 10.1093/ndtplus/sfn176.19461856
32 Abdul-Muneer PM, Chandra N, Haorah J. Interactions of oxidative stress and neurovascular inflammation in the pathogenesis of traumatic brain injury. Mol Neurobiol. 2015;51 (3 ):966–979. doi: 10.1007/s12035-014-8752-3.24865512
33 Duni A, Liakopoulos V, Roumeliotis S, et al. Oxidative stress in the pathogenesis and evolution of chronic kidney disease: untangling Ariadne’s thread. Int J Mol Sci. 2019;20 (15 ):3711. doi: 10.3390/ijms20153711.31362427
34 Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018;33 (Suppl. 3 ):iii35–iii40. doi: 10.1093/ndt/gfy175.30281126
35 Mihai S, Codrici E, Popescu ID, et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res. 2018;2018 :2180373. doi: 10.1155/2018/2180373.30271792
36 Chen S, Xiao J, Cai W, et al. Association of the systemic immune-inflammation index with anemia: a population-based study. Front Immunol. 2024;15 :1391573. doi: 10.3389/fimmu.2024.1391573.38799419
37 Alshuweishi Y, Alfaifi M, Almoghrabi Y, et al. A retrospective analysis of the association of neutrophil–lymphocyte ratio (NLR) with anemia in the Saudi population. Medicina. 2023;59 (9 ):1592. doi: 10.3390/medicina59091592.37763711
38 Sun Z, Shao H, Liu H, et al. Anemia in elderly rheumatoid arthritis patients: a cohort study. Arch Med Sci. 2024;20 (2 ):457–463. doi: 10.5114/aoms/172443.38757043
39 Zhang X, Huang J-X, Tang M, et al. A comprehensive analysis of the association between anemia and systemic inflammation in older patients with cancer. Support Care Cancer. 2023;32 (1 ):39. doi: 10.1007/s00520-023-08247-8.38110562
40 Allen DA, Breen C, Yaqoob MM, et al. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med. 1999;47 (5 ):204–211.
41 Goicoechea M, Martin J, de Sequera P, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998;54 (4 ):1337–1343. doi: 10.1046/j.1523-1755.1998.00084.x.9767553
42 Prakash J, Raja R, Mishra RN, et al. High prevalence of malnutrition and inflammation in undialyzed patients with chronic renal failure in developing countries: a single center experience from eastern India. Ren Fail. 2007;29 (7 ):811–816. doi: 10.1080/08860220701573491.17994448
43 Canali S, Core AB, Zumbrennen-Bullough KB, et al. Activin B induces noncanonical SMAD1/5/8 signaling via BMP type I receptors in hepatocytes: evidence for a role in hepcidin induction by inflammation in male mice. Endocrinology. 2016;157 (3 ):1146–1162. doi: 10.1210/en.2015-1747.26735394
44 Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306 (5704 ):2090–2093. doi: 10.1126/science.1104742.15514116
45 Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009;113 (21 ):5277–5286. doi: 10.1182/blood-2008-12-195651.19293425
46 La Ferla K, Reimann C, Jelkmann W, et al. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J. 2002;16 (13 ):1811–1813. doi: 10.1096/fj.02-0168fje.12223449
47 Jelkmann W. Regulation of erythropoietin production. J Physiol. 2011;589 (Pt 6 ):1251–1258. doi: 10.1113/jphysiol.2010.195057.21078592
48 Moldawer LL, Marano MA, Wei H, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J. 1989;3 (5 ):1637–1643. doi: 10.1096/fasebj.3.5.2784116.2784116
49 Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73 (3 ):924–967. doi: 10.1124/pharmrev.120.000096.34088867
50 Heine GH, Ortiz A, Massy ZA, et al. Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol. 2012;8 (6 ):362–369. doi: 10.1038/nrneph.2012.41.22410492
51 Rogacev KS, Zawada AM, Emrich I, et al. Lower Apo A-I and lower HDL-C levels are associated with higher intermediate CD14++CD16+ monocyte counts that predict cardiovascular events in chronic kidney disease. Arterioscler Thromb Vasc Biol. 2014;34 (9 ):2120–2127. doi: 10.1161/ATVBAHA.114.304172.25060791
52 Placke T, Salih HR, Kopp HG. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J Immunol. 2012;189 (1 ):154–160. doi: 10.4049/jimmunol.1103194.22649191
53 Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20 (5 ):576–590. doi: 10.1016/j.ccr.2011.09.009.22094253
54 Yuan Q, Wang J, Peng Z, et al. Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). J Transl Med. 2019;17 (1 ):86. doi: 10.1186/s12967-019-1808-4.30876475
55 Zhao WM, Tao SM, Liu GL. Neutrophil-to-lymphocyte ratio in relation to the risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2020;42 (1 ):1059–1066. doi: 10.1080/0886022X.2020.1832521.33081569
56 Lai W, Xie Y, Zhao X, et al. Elevated systemic immune inflammation level increases the risk of total and cause-specific mortality among patients with chronic kidney disease: a large multi-center longitudinal study. Inflamm Res. 2023;72 (1 ):149–158. doi: 10.1007/s00011-022-01659-y.36352033
57 Li G, Yu J, Jiang S, et al. Systemic immune-inflammation index was significantly associated with all-cause and cardiovascular-specific mortalities in patients receiving peritoneal dialysis. J Inflamm Res. 2023;16 :3871–3878. doi: 10.2147/JIR.S426961.37671129
